文献速递中医内科中药与中成药合理使用

宣白生脉饮对COVID-19患者疾病进展与病毒RNA清除的回顾性研究

Effectiveness of Xuanbai Shengmai Decoction, a compound Chinese herbal medicine, on disease progress and viral RNA shedding in COVID-19 patients: A retrospective study of medical chart in China.
PubMed 文献 · J Integr Med · 2025-10-13

该回顾性研究纳入2022年12月至2023年1月的212例COVID-19病例,按是否使用宣白生脉饮(XB)分为两组,采用Kaplan-Meier法和Cox模型分析。结果显示XB组死亡风险低于非XB组(尤其重症),且能缩短病毒RNA清除时间,入院1-2天内干预效果尤佳。

要点

  • XB组重症患者死亡风险低于非XB组
  • XB治疗可缩短病毒RNA清除时间
  • 入院1-2天内使用XB效果更佳

核心结论

  • 宣白生脉饮治疗COVID-19有效,尤其可降低重症患者死亡率,可能作为SARS-COV-2感染的替代治疗。

研究设计与样本

  • 回顾性研究,收集2022年12月至2023年1月212例COVID-19病例的医疗记录,按是否使用宣白生脉饮分为XB组(63例)和非XB组(149例)。

主要发现

  • XB组临床特征和CT表现较非XB组更严重,但XB组死亡风险低于非XB组,尤其在重症病例中。
  • XB治疗显著降低不良结局风险,并缩短病毒RNA清除时间。
  • 入院后1-2天内进行XB干预被证实特别有效。

关键数值与推荐

  • 共纳入212例COVID-19病例,XB组63例,非XB组149例;128例(60.4%)为男性,中位年龄75.00岁,72.6%有一种或以上基础疾病。
  • 入院时最常见症状为咳嗽(64.6%)、发热(39.6%)、喘息(27.8%)和咳痰(13.2%)。
  • 两组性别、年龄组分布、吸烟和饮酒无显著差异(P > 0.05)。

临床怎么用

  • 对于COVID-19患者,尤其重症病例,可考虑使用宣白生脉饮以降低死亡风险并促进病毒RNA清除。
  • 建议在入院后1-2天内尽早开始宣白生脉饮干预,以获取更佳效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the clinical features and effectiveness of Xuanbai Shengmai Decoction (XB, a compound Chinese herbal medicine) on disease progression, clinical effect and viral RNA shedding in COVID-19 cases. METHODS: We collected demographic and clinical information of 212 COVID-19 cases from December 2022 to January 2023, and divided these cases into two groups based on whether XB was used or not. Survival curves in the two groups were estimated by the Kaplan-Meier method. A smoothing approximation of time-to-event distributions was created based on a log-rank test and a restricted mean survival time model, and the Gaussian density estimation method. In addition, the effect of XB treatment on survival time was assessed using a series of Cox proportional hazards models. RESULTS: Of all 212 COVID-19 cases, there were respectively 63 and 149 cases reported in XB group and non-XB group. Of those, 128 (60.4%) were male, with median age of 75.00 years, and 72.6% had one or more underlying medical conditions. The most common symptoms on admission were cough (64.6%), fever (39.6%), wheezing (27.8%) and sputum (13.2%). In addition, the gender, age group distribution, smoking, and drinking between two groups were of no significant difference (P > 0.05). However, the clinical characteristics and CT findings in XB group were more serious than those in non-XB group. Nevertheless, the hazard of death in XB group was lower than that in non-XB group, especially on severe cases. Treatment with XB significantly protected against adverse outcomes, shorten the time of viral RNA shedding. Moreover, interventional therapy of XB within 1-2 days after hospital admission is confirmed with particularly effectiveness. CONCLUSION: Treatment of XB is effective for COVID-19 cases, particularly in reducing the mortality rate of severe cases, suggesting that XB may be used as an alternative treatment of SARS-COV-2 infection. Please cite this article as: Liu TW, Zhang SW, Jiang H, Yang SW, Guo YJ, Ding MY, Li XC, Xu J, Lu HT, Ye HR, Hu YH, Li R, Wei YM, Song MF, Wang S, Zhang J, Feng QS, Xu XL. Effectiveness of Xuanbai Shengmai Decoction, a compound Chinese herbal medicine, on disease progress and viral RNA shedding in COVID-19 patients: A retrospective study of medical chart in China. J Integr Med. 2026; 24(1):115-124.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Liu TW, Zhang SW, Jiang H, et al. Effectiveness of Xuanbai Shengmai Decoction, a compound Chinese herbal medicine, on disease progress and viral RNA shedding in COVID-19 patients: A retrospective study of medical chart in China. J Integr Med. 2025. PMID: 41177681. doi:10.1016/j.joim.2025.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。